The estimated Net Worth of Asset Management, Lp Chen B... is at least $90.8 Milhão dollars as of 31 October 2018. Asset B owns over 133,333 units of Axonics Inc stock worth over $88,374,890 and over the last 8 years Asset sold AXNX stock worth over $2,459,652.
Sign up
Asset B AXNX stock SEC Form 4 insiders trading
Asset has made over 11 trades of the Axonics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Asset bought 133,333 units of AXNX stock worth $1,999,995 on 31 October 2018.
The largest trade Asset's ever made was selling 504,027 units of Axonics Inc stock on 14 December 2017 worth over $2,459,652. On average, Asset trades about 211,839 units every 66 days since 2016. As of 31 October 2018 Asset still owns at least 1,285,827 units of Axonics Inc stock.
You can see the complete history of Asset B stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Axonics Inc
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik, eGeoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
What does Axonics Inc do?
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
What does Axonics Inc's logo look like?
Complete history of Asset B stock trades at Proteostasis Therapeutics Inc, Kiniksa Pharmaceuticals International Plc, Kezar Life Sciences Inc, eAxonics Inc
Axonics Inc executives and stock owners
Axonics Inc executives and other stock owners filed with the SEC include:
-
Raymond Cohen,
Chief Executive Officer, Director -
Dan Dearen,
President, Chief Financial Officer -
Rinda Sama,
Chief Operating Officer -
Raymond W. Cohen,
CEO & Director -
Danny L. Dearen,
Pres & CFO -
Dr. Karen L. Noblett M.D., M.A.S.,
Chief Medical Officer -
Rinda K. Sama,
Chief Operating Officer -
Robert McNamara,
Independent Director -
Juliet Tammenoms Bakker,
Independent Director -
Alfred J. Ford Jr.,
Chief Commercial Officer -
Erik Amble,
Independent Director -
Michael Carrel,
Independent Chairman of the Board -
Jane Kiernan,
Independent Director -
Nancy Snyderman,
Independent Director -
Karen Noblett,
Chief Medical Officer -
Prabodh Mathur,
Chief Product Development Officer -
Alfred Ford,
Chief Commercial Officer -
John Woock,
Chief Marketing Officer -
Dr. Karen L. Noblett M.A.S., M.D.,
Chief Medical Officer -
Michael V. Williamson Esq., J.D.,
Sr. VP, Gen. & IP Counsel -
Michael V. Williamson,
Sr. VP, Gen. & IP Counsel -
Dr. John Woock Ph.D.,
Exec. VP, Chief Marketing & Strategy Officer -
Aaron Pettit,
Gen. Counsel & Chief Compliance Officer -
Neil Bhalodkar,
VP of Investor Relations -
Guangqiang Jiang Ph.D.,
Chief Technology Officer -
Esteban Lopez,
-
John George Petrovich,
Director -
Shahzad Malik,
Director -
Life Sciences Llp Advent Li...,
-
Partners Bio Discovery 4 Fc...,
-
E. Mann Foundation For Scie...,
-
Capital Partners Iii, Llcen...,
-
Innovation V Ltd Neo Med In...,
-
Healthcare Holding B.V.Gild...,
-
Asset Management, Lp Chen B...,
-
Michael V. Williamson,
SVP, General Counsel -
Guangqiang Jiang,
Chief Technology Officer -
Zhong Zac & Cloud Holdings ...,
-
Raphael Wisniewski,
-
Robert E Mcnamara,
-
Geoff Pardo,
-
David M Demski,
-
Kari Leigh Keese,
Chief Financial Officer